Matrix metalloproteinase
From Proteopedia
(Difference between revisions)
Line 37: | Line 37: | ||
account for the entire binding effect between MT1-MMP and TIMP-1. Statistical analysis of the <scene name='MT1-MMP-TIMP-1_complex/Cv2/15'>key hydrogen bond</scene> stabilities in the TIMP-1 T98L mutant reveals that the hydrogen bonds network in mutant form is significantly more stable than that in WT-TIMP-1. Mutations that enhance hydrogen | account for the entire binding effect between MT1-MMP and TIMP-1. Statistical analysis of the <scene name='MT1-MMP-TIMP-1_complex/Cv2/15'>key hydrogen bond</scene> stabilities in the TIMP-1 T98L mutant reveals that the hydrogen bonds network in mutant form is significantly more stable than that in WT-TIMP-1. Mutations that enhance hydrogen | ||
bond stability contribute to the stability of the bound-like, less flexible, conformation of TIMP-1, which eventually results in increasing binding affinity for MT1-MMP. Thus, mutation affected the instrinsic dynamics of the inhibitor rather than its structure, thereby facilitating the interaction <ref name="Grossman">PMID:20545310</ref>. | bond stability contribute to the stability of the bound-like, less flexible, conformation of TIMP-1, which eventually results in increasing binding affinity for MT1-MMP. Thus, mutation affected the instrinsic dynamics of the inhibitor rather than its structure, thereby facilitating the interaction <ref name="Grossman">PMID:20545310</ref>. | ||
+ | |||
+ | ==3D structures of matrix metalloproteinase== | ||
+ | [[Matrix metalloproteinase 3D structures]] | ||
+ | |||
</StructureSection> | </StructureSection> | ||
Line 126: | Line 130: | ||
*MMP13 collagenase 3 | *MMP13 collagenase 3 | ||
- | **[[1cxv]] - MMP catalytic domain - mouse<BR /> | ||
**[[1pex]] – hMMP hemopexin-like domain<br /> | **[[1pex]] – hMMP hemopexin-like domain<br /> | ||
**[[2yig]], [[3ljz]], [[3kec]], [[3kej]], [[3kek]], [[3kry]], [[3i7g]], [[3i7i]], [[3elm]], [[2pjt]], [[2ozr]], [[1xuc]], [[1xud]], [[1xur]], [[1you]], [[1ztq]], [[3o2x]], [[3zxh]], [[4a7b]], [[1fls]], [[1fm1]], [[456c]], [[830c]], [[3tvc]], [[4jp4]], [[4jpa]], [[3wv1]], [[3wv2]], [[3wv3]], [[4l19]], [[5b5o]], [[5b5p]], [[5bot]], [[5boy]], [[5bpa]] – hMMP catalytic domain + inhibitor<br /> | **[[2yig]], [[3ljz]], [[3kec]], [[3kej]], [[3kek]], [[3kry]], [[3i7g]], [[3i7i]], [[3elm]], [[2pjt]], [[2ozr]], [[1xuc]], [[1xud]], [[1xur]], [[1you]], [[1ztq]], [[3o2x]], [[3zxh]], [[4a7b]], [[1fls]], [[1fm1]], [[456c]], [[830c]], [[3tvc]], [[4jp4]], [[4jpa]], [[3wv1]], [[3wv2]], [[3wv3]], [[4l19]], [[5b5o]], [[5b5p]], [[5bot]], [[5boy]], [[5bpa]] – hMMP catalytic domain + inhibitor<br /> | ||
**[[2e2d]] - hMMP catalytic domain + TIMP-2<br /> | **[[2e2d]] - hMMP catalytic domain + TIMP-2<br /> | ||
**[[4fu4]], [[4fvl]], [[4g0d]] - hMMP catalytic domain (mutant) + pro-domain peptide<br /> | **[[4fu4]], [[4fvl]], [[4g0d]] - hMMP catalytic domain (mutant) + pro-domain peptide<br /> | ||
+ | **[[6hv2]] - hMMP catalytic domain + peptide<br /> | ||
+ | **[[1cxv]] - MMP catalytic domain - mouse<BR /> | ||
*MMP14 Membrane T1 | *MMP14 Membrane T1 | ||
**[[3ma2]] – hMMP residues 112-292 + TIMP-1 (mutant) <BR /> | **[[3ma2]] – hMMP residues 112-292 + TIMP-1 (mutant) <BR /> | ||
- | **[[1buv]], [[1bqq]] - hMMP + TIMP-2<BR /> | + | **[[1buv]], [[1bqq]] residues 112-292 hMMP + TIMP-2<BR /> |
- | **[[3c7x]] – hMMP hemopexin- | + | **[[5h0u]] - hMMP residues 112-292 + polyHis<br /> |
+ | **[[3c7x]] – hMMP hemopexin domain residues 316-511<br /> | ||
+ | **[[6cm1]], [[6clz]] – hMMP hemopexin domain + apolipoprotein<br /> | ||
**[[2mqs]] - hMMP + collagen<br /> | **[[2mqs]] - hMMP + collagen<br /> | ||
- | **[[5h0u]] - hMMP + polyHis<br /> | ||
*MMP16 Membrane T3 | *MMP16 Membrane T3 |
Revision as of 09:07, 29 October 2019
|
3D structures of matrix metalloproteinase
Updated on 29-October-2019
References
- ↑ Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999 Jul 30;274(31):21491-4. PMID:10419448
- ↑ Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011 Jan;278(1):16-27. doi: 10.1111/j.1742-4658.2010.07919.x. Epub 2010, Nov 19. PMID:21087457 doi:http://dx.doi.org/10.1111/j.1742-4658.2010.07919.x
- ↑ Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009 May;21(5):1323-33. PMID:19360311
- ↑ Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal diseases. J Periodontol. 1993 May;64(5 Suppl):474-84. PMID:8315570 doi:http://dx.doi.org/10.1902/jop.1993.64.5s.474
- ↑ Grossman M, Tworowski D, Dym O, Lee MH, Levy Y, Murphy G, Sagi I. Intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and effects its function. Biochemistry. 2010 Jun 14. PMID:20545310 doi:10.1021/bi902141x